A U.S. district court ruled in favor of AstraZeneca’s patent protection for Seroquel XR, the long-acting version of Seroquel. This follows AstraZeneca’s failure to prevent the FDA from approving generic versions of Seroquel, exposing the company to one of the largest losses to drug-patent expirations in the pharmaceutical sector. A U.K. court has denied AstraZeneca’s request for protection of Seroquel XR’s patent.
Article → Related Articles:
Bloomberg
Reauters
